Endocrine Abstracts

The Sodium Iodide Symporter (NIS) is responsible for active transport of iodide into thyroid cells. Its expression in thyroid tumors allows the use of radioactive iodine (131I) as co-adjuvant therapeutic tool to eliminate remaining tumor cells and metastases after total thyroidectomy. Nevertheless, certain subsets of patients with advanced forms of thyroid cancer lose the ability to respond to radioiodine therapy, which drastically reduces their survival rates. Recent studies ...

IntroductionThe Sodium Iodide Symporter (NIS) is responsible for the active transport of iodide into thyroid cells. Most of differentiated thyroid carcinomas (TC) retain the functional expression of NIS, which allows the use of radioiodide (RAI) as the systemic treatment of choice for metastatic disease. Still, a significant proportion of patients with advanced thyroid cancer fail to respond to RAI therapy (refractory-TC), which makes their management ve...

Introduction: The Sodium Iodide Symporter (NIS) is responsible for active transport of iodide into thyroid follicular cells, enabling the use of radioactive iodine (RAI) for treatment of metastatic disease. Still, a significant proportion of patients with advanced forms of thyroid cancer (TC) became refractory to RAI therapy. Defective NIS expression is the main reason for impaired iodide uptake in TC and NIS downregulation has been associated with several pathways linked to m...